Document

CRESCENT BIOPHARMA, INC.

VIA EDGAR TRANSMISSION

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

Attention: Jessica Dickerson

Re: CRESCENT BIOPHARMA, INC.

Registration Statement on Form S-1 (Registration No. 333-292600)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-292600) (as amended, the “Registration Statement”) of Crescent Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on January 15, 2026, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Wesley C. Holmes at (617) 948-6027.

If you have any questions regarding the foregoing, please do not hesitate to contact Peter N. Handrinos at (617) 948-6060 or Wesley C. Holmes at (617) 948-6027, of Latham & Watkins LLP. Thank you in advance for your consideration.

CRESCENT BIOPHARMA, INC.


By:			/s/ Barbara H. Bispham
Name:			Barbara H. Bispham
Title:			General Counsel


cc:			Peter N. Handrinos, Latham & Watkins LLP
			Wesley C. Holmes, Latham & Watkins LLP